Jonathan S. Berek
Academic Appointments
Key Documents
Contact Information
-
Clinical Offices
Stanford Women's Cancer Center 900 Blake Wilbur Dr 1st Floor MC 5854 Palo Alto, CA 94304 Tel Work (650) 498-6004 Fax (650) 498-7237Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information Email Tel (650) 723-5533Alternate Contact Kerry Garcia Assistant to the Chair Email Tel Work 650-723-5533Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Gynecologic Cancer
- Gynecologic Oncology
- Gynecologic Cancers - Gynecologic Oncology
- Ovarian Cancer
- Uterine Cancer
- Uterine Cervical Cancer
Administrative Appointments
- Laurie Kraus Lacob Professor, Stanford (2012 - present)
- Chair, Department of Obstetrics and Gynecology, Stanford University School of Medicine (2005 - present)
- Director, Stanford Women's Cancer Center, Stanford Cancer Institute (2008 - present)
Professional Education
| Residency: | Harvard Medical School, Brigham & Women's Hospital MA (1979) |
| Fellowship: | UCLA - School of Medicine CA (1981) |
| Internship: | Harvard Medical School, Brigham & Women's Hospital MA (1976) |
| Medical Education: | Johns Hopkins University School of Medicine MD (1975) |
| Biomedical Sciences: | Brown University, MMS (1973) |
| Board Certification: | Gynecologic Oncology, American Board of Obstetrics and Gynecology (1983) |
Community and International Work
- President, Council of University Chairs of Obstetrics and Gynecology (CUCOG), US&suffix=physician
- Immediate Past President, International Gynecologic Cancer Society, International&suffix=physician
Scientific Focus
Clinical Trials
- Not Recruiting A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
- Recruiting Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
- Recruiting Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
- Recruiting Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
- Not Recruiting Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy
Publications
- Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. J Clin Oncol. 2013; (12): 1554-61
- Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study. Obstet Gynecol. 2013; (4): 709-716
- Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2012: S118-29
- Current management of vulvar cancer. Hematol Oncol Clin North Am. 2012; (1): 45-62
- FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage. Nat Commun. 2012: 1000
- Personalizing CA125 levels for ovarian cancer screening. Cancer Prev Res (Phila). 2011; (9): 1356-9
Help
Trial Administration